GSDMD and Alzheimer disease: Sebastiaan Moonen et al. investigated multiple cases of symptomatic AD and pathologically defined preclinical AD and found that expression of cleaved GSDMD, the pyroptosis effector protein, was increased in the brains of AD patients compared to controls, particularly in microglia (Moonen et al., 2023).